newsfilter
← Latest News
GlobeNewswire·

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept